ID   MCF10A-ERBB2m-1
AC   CVCL_C7QP
SY   MCF10A-ERBB2_type-01; 06M15006
DR   CancerTools; 161190
DR   Wikidata; Q117704667
RX   PubMed=30787176;
WW   Info; FTRP; -; https://www.fmu.ac.jp/home/trc/en/contract-research-provision/human-gene-overexpressing-cell-lines/
CC   Part of: Fukushima Translational Research Project gene-overexpressing cell lines panel.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:3430; ERBB2 (Note=With p.Gly309Ala (c.926G>C)).
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008367.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0598 ! MCF-10A
SX   Female
AG   36Y
CA   Spontaneously immortalized cell line
DT   Created: 21-03-23; Last updated: 10-04-25; Version: 5
//
RX   PubMed=30787176; DOI=10.1158/1535-7163.MCT-18-1085;
RA   Irie H., Ito K., Fujioka Y., Oguchi K., Fujioka A., Hashimoto A.,
RA   Ohsawa H., Tanaka K., Funabashi K., Araki H., Kawai Y., Shimamura T.,
RA   Wadhwa R., Ohkubo S., Matsuo K.;
RT   "TAS0728, a covalent-binding, HER2-selective kinase inhibitor shows
RT   potent antitumor activity in preclinical models.";
RL   Mol. Cancer Ther. 18:733-742(2019).
//